Pharmacokinetics of High‐Dose Abetimus Sodium in Normal Subjects With Specific Assessment of Effect on Coagulation
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
Abetimus sodium is an oligonucleotide‐based investigational drug designed to treat patients with lupus nephritis by specifically reducing anti‐double‐stranded DNA antibody levels. The safety and pharmacokinetics of abetimus were evaluated in 24 healthy volunteers at intravenous doses of 600 mg, 1200 mg, and 2400 mg. The mean half‐life ranged from 0.8 to 1.5 hours. Maximum exposure assessed by maximum observed plasma concentration was dose proportional. Total exposure assessed by area under the plasma concentration—time curve was dose proportional between 1200‐mg and 2400‐mg doses and greater than proportionate between the 600‐mg and 1200‐mg doses. Abetimus was well tolerated in all dose groups, with adverse events observed in 33.3% (2/6) of placebo subjects and 16.7% (3/18) subjects receiving abetimus. No clinically significant effects were observed on laboratory values, vital signs, or electrocardiogram, with the exception of a transient, dose‐dependent, prolongation in activated partial thromboplastin time. In vitro coagulation studies suggested that the effect on activated partial thromboplastin time was attributable to a nonspecific interaction rather than specific factor depletion. Exposure to abetimus at intravenous doses of 600 mg, 1200 mg, and 2400 mg was well tolerated. Total exposure assessed by area under the plasma concentration—time curve was greater than dose proportional across the dose range of 600 mg to 2400 mg.
